PMID: 6161715Jan 1, 1980Paper

Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion

Cancer Chemotherapy and Pharmacology
J J GulloP V Woolley

Abstract

The pharmacokinetics of cis-dichlorodiam-minoplatinum (II) (cisplatin) have been studied in seven patients, of whom four received the drug as a one hour infusion and three received it as a 20 h infusion. The patients receiving the drug over one hour exhibited biphasic clearance of total platinum with a rapid initial phase (8.7-22.5 min) and a prolonged second phase (30.5-106 h). Free (ultrafilterable) cisplatin was readily detectable in this group and was rapidly cleared (half-life about 22 min). The volume of distribution of the drug was 50.3-65.6 liters and it was 26.6-50% excreted in the urine in 48 h. In the patients receiving the 20 h infusion, a more complex plasma elimination curve was seen, with the appearance of a secondary peak. Free drug was not detectable in these patients and they showed less urinary excretion (21.4-25.9% at 48 h) than the one hour group. Cisplatin was bound to several plasma proteins, including albumin, transferrin, and gamma-globulin. The data indicate that cisplatin is retained in the body more extensively after a 20 h infusion than after a one hour infusion.

References

Sep 1, 1978·Bioinorganic Chemistry·R StjernholmN Katayama
Mar 1, 1979·Cancer Treatment Reviews·A W PrestaykoS T Crooke
Sep 1, 1978·Chemico-biological Interactions·R C Manaka, W Wolf
Dec 1, 1978·Journal of Pharmacokinetics and Biopharmaceutics·B E Dahlström, L K Paalzow
Mar 1, 1979·Clinical Pharmacology and Therapeutics·P E GormleyR Cysyk
Dec 1, 1974·The Journal of Infectious Diseases·F C Luft, S A Kleit

❮ Previous
Next ❯

Citations

Jan 1, 1989·Cancer Chemotherapy and Pharmacology·B SchechterR Arnon
Jan 1, 1984·Journal of Cancer Research and Clinical Oncology·R B SchilcherC G Schmidt
Jan 1, 1987·European Journal of Clinical Pharmacology·H GriffithsR G Fish
Jan 1, 1988·European Journal of Clinical Pharmacology·R PreissP Michailov
Jan 1, 1995·Cancer Chemotherapy and Pharmacology·E GamelinF Larra
Jan 1, 1990·Cancer Chemotherapy and Pharmacology·B J FosterB Leyland-Jones
Jun 19, 1992·Pharmaceutisch Weekblad. Scientific Edition·T J HodesJ H Beijnen
Aug 7, 2008·Cancer Chemotherapy and Pharmacology·Claire F VerschraegenFred B Oldham
May 15, 2013·Journal of Chemical Biology·Anwen M Krause-HeuerJanice R Aldrich-Wright
Jan 1, 1990·Journal of Pharmaceutical and Biomedical Analysis·W A De WaalJ C Kraak
Mar 17, 2010·Journal of the American Society for Mass Spectrometry·Jonathan P WilliamsPeter J Sadler
May 29, 1998·Biochimica Et Biophysica Acta·J F Neault, H A Tajmir-Riahi
Sep 25, 1999·Journal of Biomolecular Structure & Dynamics·J F NeaultH A Tajmir-Riahi
Jan 1, 1992·British Journal of Clinical Pharmacology·J D HoldingP M Stell
Sep 1, 1996·The Journal of Pharmacy and Pharmacology·N NagaiH Ogata
Feb 1, 1985·Antimicrobial Agents and Chemotherapy·M D ShelleyM Adams
May 5, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gareth J VealClinton F Stewart
Aug 21, 2001·Biological & Pharmaceutical Bulletin·J S ZhangM Otagiri
Feb 7, 1998·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·D R YoungE Y Chao
Feb 11, 2000·Clinical Pharmacokinetics·F LéviG Milano
Jan 1, 2014·Journal of Medical Ultrasonics·Noboru SasakiMitsuyoshi Takiguchi
Jan 1, 1987·Cancer Chemotherapy and Pharmacology·L HegedüsH M Pinedo
Jan 1, 1983·Drug Metabolism Reviews·W E EvansP R Hutson
Jan 1, 1991·Cancer Investigation·N TanabeK Kimura
May 31, 2011·Journal of Pharmaceutical and Biomedical Analysis·Pernilla Videhult PierreHans Ehrsson
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P TothillJ F Smyth
Nov 23, 2006·European Journal of Pharmacology·Ying WangJen-Fu Chiu
Nov 17, 2010·International Journal of Pharmaceutics·Agnieszka KowalczukNeli Koseva
Feb 5, 2015·Analytical and Bioanalytical Chemistry·Julie Maria DerschBente Gammelgaard

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.